Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2011

View Archived Issues

Novel phosphodiesterase 10A inhibitors synthesized

Lotus Tissue Repair raises funds to advance treatment for dystrophic epidermolysis bullosa

Johns Hopkins University and Innogene Kalbiotech begin trial for lung cancer vaccine

ISC-4 exhibits safety and antitumor activity in murine model of human colon cancer

Preclinical study supports further evaluation of dovitinib in Waldenstrom's macroglobulinemia

Leukothera shows synergistic activity with chemotherapeutic agents in leukemia cell lines

New lysophospholipid S1P1 receptor agonists presented by Almirall

Roche discloses new glycogen synthase activators

Bristol-Myers Squibb and Innate Pharma enter global agreement for IPH-2102

INV-144 enters phase IIa trial to slow kidney disease in patients with hypertension and diabetes

Novel nuclear receptor related 1 receptor ligands patented by Sanofi

Novel PI3K inhibitors prepared

Dainippon Sumitomo and AstraZeneca claim new Toll-like receptor modulators

Vantia Therapeutics raises funds to develop VA-106483 and VA-111913

Roche discloses novel series of monoamine reuptake inhibitors

Dual mTORC1/mTORC2 inhibition may enhance treatment of acute myeloid leukemia

Metabolic Solutions receives funds from the Alzheimer's Drug Discovery Foundation

Zafgen secures financing for phase II trial in obesity

INNO-206 shows safety in ongoing phase Ib trial in soft tissue sarcoma

IDMC recommmends continuation of phase III VENICE trial of Zaltrap in advanced prostate cancer

Merck KGaA to discontinue development of Toll-like receptor 9 agonist IMO-2055

Amylin Pharmaceuticals, Lilly and Alkermes report on tQT study of Bydureon

Phase III EXIST-1 trial of Afinitor in tuberous sclerosis meets primary endpoint

TMC-435 receives FDA fast track status in chronic hepatitis C genotype 1

Amsterdam Molecular Therapeutics requests reexamination of MAA for gene therapy Glybera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...